文献速递贫血与红细胞疾病

直接抗人球蛋白试验阴性自身免疫性溶血性贫血的临床特征与预后

[Clinical characteristics and prognosis of patients with direct antiglobulin test-negative autoimmune hemolytic anemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

单中心回顾性队列研究纳入30例DAT阴性AIHA患者,占同期AIHA住院病例4.77%。一线糖皮质激素总缓解率93.3%,中位随访64个月全因死亡率10.0%,中位EFS 17.0个月。完善排除性诊断后该亚型预后相对良好。

要点

  • DAT阴性AIHA占同期AIHA住院病例4.77%,以原发性(86.7%)和女性(66.7%)为主。
  • 一线糖皮质激素总缓解率93.3%,二线以利妥昔单抗为主。
  • 复发诱因主要为药物减撤(73.7%)及感染(21.1%)。

核心结论

  • 完善排除性诊断并排除IgA/IgM介导型后,DAT阴性AIHA预后相对良好,对糖皮质激素及利妥昔单抗等免疫抑制治疗反应相对理想。

研究设计与样本

  • 单中心回顾性队列研究,纳入2014年1月至2023年12月中国医学科学院血液病医院收治的30例DAT阴性AIHA患者。
  • 入组病例经微柱凝胶法广谱及单特异性抗血清检测均呈阴性,并严格排除其他溶血性疾病。

主要发现

  • 30例DAT阴性AIHA占同期AIHA住院病例4.77%,女性20例(66.7%)、男性10例(33.3%),原发性26例(86.7%)、继发性4例(13.3%)。
  • 确诊年龄(44.8±17.8)岁,起病后最低HGB为(61.3±15.9)g/L。
  • 一线糖皮质激素总缓解率达93.3%(28/30),二线治疗以利妥昔单抗为主。
  • 中位随访64个月,全因死亡率为10.0%(3/30),中位EFS为17.0个月,1年、3年及5年EFS率分别为56.5%、45.9%和37.5%。
  • 复发诱因主要为药物减撤(73.7%)及感染(21.1%)。

关键数值与推荐

  • DAT阴性判定采用微柱凝胶法广谱及单特异性抗血清检测均呈阴性。
  • 一线糖皮质激素总缓解率93.3%(28/30)。
  • 中位EFS 17.0个月,1年、3年及5年EFS率分别为56.5%、45.9%和37.5%。

临床怎么用

  • 对DAT阴性疑似AIHA患者应完善排除性诊断,排除其他溶血性疾病及IgA/IgM介导型AIHA。
  • 一线可选用糖皮质激素,二线可选用利妥昔单抗等免疫抑制治疗。
  • 糖皮质激素无效者可尝试伊布替尼联合利妥昔单抗或环孢素联合利妥昔单抗挽救治疗。

局限性

  • 本研究为单中心回顾性队列研究,样本量30例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical characteristics and outcomes of direct antiglobulin test (DAT) -negative autoimmune hemolytic anemia (AIHA) and to provide evidence for the clinical diagnosis and management of this subtype. Methods: This was a single-center retrospective cohort study. Thirty patients with DAT-negative AIHA who were treated at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, between January 2014 and December 2023 were included. All included patients tested negative by the microcolumn gel method using both polyspecific and monospecific antiglobulin reagents, and those with other causes of hemolytic anemia were rigorously excluded. The patients' baseline laboratory parameters, outcomes, and treatment responses were analyzed. Results: A total of 30 patients with DAT-negative AIHA were included, accounting for 4.77% of all patients hospitalized with AIHA during the same period; 20 (66.7%) were female and 10 (33.3%) were male; 26 (86.7%) had primary AIHA and 4 (13.3%) had secondary AIHA cases. The age at diagnosis was (44.8±17.8) years. The nadir hemoglobin level at disease onset was (61.3±15.9) g/L. The overall response rate to first-line glucocorticoid therapy was 93.3% (28/30), and rituximab was the most commonly used second-line treatment. Both patients who failed to respond to glucocorticoids achieved remission following salvage treatment with ibrutinib plus rituximab and cyclosporine plus rituximab. At a median follow-up of 64 months, the all-cause mortality rate was 10.0% (3/30). The median event-free survival (EFS) was 17.0 months, with 1-, 3-, and 5-year EFS rates of 56.5%, 45.9%, and 37.5%, respectively. Relapses were mainly triggered by drug tapering (73.7%) and infection (21.1%) . Conclusion: After a comprehensive diagnostic workup to exclude other causes and immunoglobulin A (IgA) - or IgM-mediated AIHA, patients with DAT-negative AIHA generally have a relatively favorable prognosis and show good responses to glucocorticoids, rituximab, and other immunosuppressive therapies. 目的: 探讨直接抗人球蛋白试验(Direct antiglobulin test,DAT)阴性自身免疫性溶血性贫血(Autoimmune hemolytic anemia,AIHA)的临床特征及转归,为该亚型的临床诊疗提供依据。 方法: 本研究为单中心回顾性队列研究。分析2014年1月至2023年12月中国医学科学院血液病医院收治的30例DAT阴性AIHA患者。入组病例经微柱凝胶法广谱及单特异性抗血清检测均呈阴性,并严格排除其他溶血性疾病。对患者基线实验室指标、治疗反应及转归进行分析。 结果: 共纳入30例DAT阴性AIHA患者,占同期AIHA住院病例的4.77%,其中女性20例(66.7%),男性10例(33.3%),原发性26例(86.7%),继发性4例(13.3%),确诊年龄(44.8±17.8)岁。起病后最低HGB为(61.3±15.9)g/L。一线糖皮质激素总缓解率达93.3%(28/30),二线治疗以利妥昔单抗为主。2例糖皮质激素无效者经伊布替尼+利妥昔单抗及环孢素+利妥昔单抗挽救获完全缓解。中位随访64个月,全因死亡率为10.0%(3/30),中位无事件生存(EFS)期17.0个月,1年、3年及5年EFS率分别为56.5%、45.9%和37.5%。复发诱因主要为药物减撤(73.7%)及感染(21.1%)。 结论: 在完善排除性诊断并排除IgA/IgM介导型后,DAT阴性AIHA预后相对良好,对糖皮质激素及利妥昔单抗等多种免疫抑制治疗反应相对理想。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang JA, Qiu JW, Shi J, et al. [Clinical characteristics and prognosis of patients with direct antiglobulin test-negative autoimmune hemolytic anemia]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42851175. doi:10.3760/cma.j.cn121090-20260507-00227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。